Vascular endothelial growth factor and diabetic macular edema

Survey of Ophthalmology

Volumn 61, Issue 6, 2016, Pages 759-768

  Lally, David R ^a   Shah, Chirag P ^a   Heier, Jeffrey S ^a  

^a OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

Author keywords

aflibercept; bevacizumab; diabetes; diabetic macular edema; diabetic retinopathy; intravitreal anti VEGF; laser photocoagulation; ranibizumab; retina; vascular endothelial growth factor; VEGF

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; GLUCOSE; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A;

BLOOD RETINA BARRIER; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; ENDOPHTHALMITIS; GLUCOSE BLOOD LEVEL; HEALTH CARE SYSTEM; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; MICROANEURYSM; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREVALENCE; PRIORITY JOURNAL; RETINAL THICKNESS; REVIEW; UPREGULATION; VISUAL ACUITY; VISUAL IMPAIRMENT; ANTAGONISTS AND INHIBITORS; COMPLICATION; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; GLOBAL HEALTH; INCIDENCE; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; METABOLISM; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; RETINA;

ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; GLOBAL HEALTH; HUMANS; INCIDENCE; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; RETINA; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84965164057     PISSN: 00396257     EISSN: 18793304     Source Type: Journal    
DOI: 10.1016/j.survophthal.2016.03.010     Document Type: Review

References (76)

1. 1 Abicipar and multi-VEGF/PDGF DARPin. Molecular Partners website. Available at: http://www.molecularpartners.com/our-products/abiciparandmulti-vegf_pdgf/. Published January 15, 2004. Updated October 20, 2014. Accessed January 4, 2016.
2. 2 American Diabetes Association. Standards of medical care in diabetes: 2013. Diabetes Care 36:suppl 1 (2013), S11–S66.
3. 3 American Academy of Ophthalmology Retina/Vitreous PPP Panel. Preferred Practice Pattern guidelines: diabetic retinopathy. 2014, American Academy of Ophthalmology, San Francisco, CA.
4. 4 Arevalo, J.F., Sanchez, J.G., Fromow-Guerra, J., et al., Pan-American Collaborative Retina Study Group (PACORES). Comparison of two doses of primary intravitreal bevacizumab (Avastin) for diffuse macular edema: results from the Pan-American Collaborative Retina Study Group (PACORES) at 12-month follow-up. Graefes Arch Clin Exp Ophthalmol 247:6 (2009), 735–743.
5. 5 Benarous, R., Sasongko, M.B., Qureshi, S., et al. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. Invest Ophthalmol Sci 52:10 (2011), 7464–7469.
6. 6 Bressler, S.B., Almukhtar, T., Bhorade, A., et al., Diabetic retinopathy clinical research network investigators. Repeated intravitreous ranibizumab injections for diabetic macular edema and the risk of sustained elevation of intraocular pressure or the need for ocular hypotensive treatment. JAMA Ophthalmol 133:5 (2015), 589–597.
7. 7 Bressler, S.B., Melia, M., Glassman, A.R., et al. Ranibizumab plus prompt or deferred laser for diabetic macular edema in eyes with vitrectomy before anti-vascular endothelial growth factor therapy. Retina 35:12 (2015), 2516–2528.
8. 8 Bressler, N.M., Varma, R., Doan, Q.V., et al. Underuse of the health care system by persons with diabetes mellitus and diabetic macular edema in the United States. JAMA Ophthalmol 132:2 (2014), 168–173.
9. 9 Brown, D.M., Nguyen, Q.D., Marcus, D.M., et al. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials. Ophthalmology 120 (2013), 2013–2022.
10. 10 Brown, D.M., Schmidt-Erfurth, U., Do, D.V., et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies. Ophthalmology 122 (2015), 2044–2052.
11. 11 Chun, D.W., Heier, J.S., Topping, T.M., et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology 113:10 (2006), 1706–1712.
12. 12 Cunningham, E.T. Jr., Adamis, A.P., Altaweel, M., et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112:10 (2005), 1747–1757.
13. 13 Diabetic Retinopathy Clinical Research Network. A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 114:10 (2007), 1860–1867.
14. 14 Diabetic Retinopathy Clinical Research Network, Elman, M.J., Aiello, L.P., Beck, R.W., et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117:6 (2010), 1064–1077.
15. 15 Diabetic Retinopathy Clinical Research Network, Elman, M.J., Bressler, N.M., Qin, H., et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118:4 (2011), 609–614.
16. 16 Diabetic Retinopathy Clinical Research Network, Elman, M.J., Qin, H., Aiello, L.P., et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology 119:11 (2012), 2312–2318.
17. 17 Diabetic Retinopathy Clinical Research Network, Wells, J.A., Glassman, A.R., et al. Aflibercept, bevacizumab or ranibizumab for diabetic macular edema. N Engl J Med 372:13 (2015), 1193–1203.
18. 18 Ding, J., Wong, T.Y., Current epidemiology of diabetic retinopathy and diabetic macular edema. Curr Diab Rep 12:4 (2012), 346–354.
19. 19 Do, D.V., Nguyen, Q.D., Boyer, D., et al. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 119:8 (2012), 1658–1665.
20. 20 Do, D.V., Nguyen, Q.D., Khwaja, A.A., et al. Ranibizumab for edema of the macula in diabetes study: 3-year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 131:2 (2013), 139–145.
21. 21 Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study Research Group report number 1. Arch Ophthalmol 103:12 (1985), 1796–1806.
22. 22 Elman, M.J., Ayala, A., Bressler, N.M., et al., Diabetic Retinopathy Clinical Research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: 5-year randomized trial results. Ophthalmology 122 (2015), 375–381.
23. 23 Emanuele, N., Moritz, T., Klein, R., et al., Veterans Affairs Diabetes Trial Study Group. Ethnicity, race, and clinically significant macular edema in the Veterans Affairs Diabetes Trial (VADT). Diabetes Res Clin Pract 86:2 (2009), 104–110.
24. 24 Funatsu, H., Yamashita, H., Nakamura, S., et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 113:2 (2006), 294–301.
25. 25 Ford, J.A., Elders, A., Shyangdan, D., et al. The relative clinical effectiveness of ranibizumab and bevacizumab in diabetic macular oedema: an indirect comparison in a systematic review. BMJ, 345, 2012, e5182.
26. 26 Humayun, M., Santos, A., Altamirano, J.C., et al. Implantable micropump for drug delivery in patients with diabetic macular edema. Transl Vis Sci Technol, 3(6), 2014, 5.
27. 27 Ip, M.S., Domalpally, A., Hopkins, J.J., et al. Long-term effects of ranibizumab on diabetic retinopathy severity and progression. Arch Ophthalmol 130:9 (2012), 1145–1152.
28. 28 Klein, B.E., Klein, R., Moss, S.E., Is serum cholesterol associated with progression of diabetic retinopathy or macular edema in persons with younger-onset diabetes of long duration?. Am J Ophthalmol 128:5 (1999), 652–654.
29. 29 Klein, R., Klein, B.E., Moss, S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy; IV: diabetic macular edema. Ophthalmology 91:12 (1984), 1464–1474.
30. 30 Klein, R., Klein, B.E., Moss, S.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthalmology 105 (1998), 1801–1815.
31. 31 Klein, R., Knudtson, M.D., Lee, K.E., et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes. Ophthalmology 116:3 (2009), 497–503.
32. 32 Klein, B.E., Myers, C., Howard, K.P., Klein, R., Serum lipids and proliferative diabetic retinopathy and macular edema in persons with long-term type 1 diabetes mellitus: The Wisconsin Epidemiologic Study of Diabetic Retinopathy. JAMA Ophthalmol 133:5 (2015), 503–510.
33. 33 Korobelnik, J.F., Do, D.V., Schmidt-Erfurth, U., et al. Intravitreal aflibercept for diabetic macular edema. Ophthalmology 121:11 (2014), 2247–2254.
34. 34 Laganovska G. First-in-human results of a refillable drug delivery implant providing release of ranibizumab in patients with neovascular AMD. Paper presented at: American Academy of Ophthalmology, Retina Subspecialty Day; 2012 Nov 9; Chicago IL.
35. 35 Lee, S.N., Chhablani, J., Chan, C.K., et al. Characterization of microaneurysm closure after focal laser photocoagulation in diabetic macular edema. Am J Ophthalmol 155:5 (2013), 905–912.
36. 36 Li, X., Xu, G., Wang, Y., et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 121:9 (2014), 1740–1747.
37. 37 Loewenstein A, Quiroz Mercado H, Guerrero Naranjo JL, et al. Interim results of a dose escalation study of NT-503 encapsulate cell therapy for the treatment of choroidal neovascularization in age-related macular degeneration. Poster presented at: Association of Research in Vision and Ophthalmology Annual Meeting; 2015 May 3-7; Denver, CO.
38. 38 Lovestam-Adrian, M., Agardh, E., Photocoagulation of diabetic macular edema—complications and visual outcome. Acta Ophthalmol Scand 78:6 (2000), 667–671.
39. 39 Man, R.E., Sasongko, M.B., Sanmugasundram, S., et al. Longer axial length is protective of diabetic retinopathy and macular edema. Ophthalmology 119:9 (2012), 1754–1759.
40. 40 Martin, D.F., Maguire, M.G., Treatment of choice for diabetic macular edema. N Engl J Med 372:13 (2015), 1260–1261.
41. 41 Massin, P., Bandello, F., Garweg, J.G., et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 33 (2010), 2399–2405.
42. 42 Maturi R. Abicipar pegol (anti-VEGF DARPin) phase 2 study in patients with neovascular age-related macular degeneration. Paper presented at: ASRS conference; 2014 Aug 12; San Diego, CA.
43. 43 Mazhar, K., Varma, R., Choudhury, F., et al. Severity of diabetic retinopathy and health-related quality of life: the Los Angeles Latino Eye Study. Ophthalmology 118:4 (2011), 649–655.
44. 44 Michaelides, M., Kaines, A., Hamilton, R.D., et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT Study): 12 month data: report 2. Ophthalmology 117 (2010), 1078–1086.
45. 45 Miljanovic, B., Glynn, R.J., Nathan, D.M., et al. A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 53:11 (2004), 2883–2892.
46. 46 Mitchell, P., Bandello, F., Schmidt-Erfurth, U., et al., RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118 (2011), 615–625.
47. 47 Morgan, C.M., Schatz, H., Atrophic creep of the retinal pigment epithelium after focal photocoagulation. Ophthalmology 96:1 (1989), 96–103.
48. 48 Moss, S.E., Klein, R., Klein, B.E., Association of cigarette smoking with diabetic retinopathy. Diabetes Care 14:2 (1991), 119–126.
49. 49 Moss, S.E., Klein, R., Klein, B.E., Cigarette smoking and ten-year progression of diabetic retinopathy. Ophthalmology 103:9 (1996), 1438–1442.
50. 50 Moss, S.E., Klein, R., Klein, B.E., The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105:6 (1998), 998–1003.
51. 51 Muhlhauser, I., Sawicki, P., Berger, M., Cigarette-smoking as a risk factor for macroproteinuria and proliferative retinopathy in type 1 (insulin-dependent) diabetes. Diabetologia 29:8 (1986), 500–502.
52. 52 Narayan, K.M., Boyle, J.P., Thompson, T.J., Sorensen, S.W., Williamson, D.F., Lifetime risk for diabetes mellitus in the United States. JAMA 290:14 (2003), 1884–1890.
53. 53 Nguyen, Q.D., Brown, D.M., Marcus, D.M., et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119 (2012), 789–801.
54. 54 Nguyen, Q.D., Shah, S.M., Khwaja, A.A., et al. READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology 117 (2010), 2146–2151.
55. 55 Nguyen, Q.D., Tatlipinar, S., Shah, S.M., et al. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. Am J Ophthalmol 142 (2006), 961–969.
56. 56 Ollendorf, D.A., Colby, J.A., Pearson, S.D., Comparative effectiveness of anti-VEGF agents for diabetic macular edema. Int J Technol Assess Health Care 29 (2013), 392–401.
57. 57 Papadopoulos, N., Martin, J., Ruan, Q., et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:2 (2012), 171–185.
58. 58 Patel, R.D., Messner, L.V., Teitelbaum, B., et al. Characterization of ischemic index using ultra-widefield fluorescein angiography in patients with focal and diffuse recalcitrant diabetic macular edema. Am J Ophthalmol 155:6 (2013), 1038–1044.
59. 59 Pruente C. Efficacy and safety of ranibizumab in two treat-and-extend versus pro-re-nata regimes in patients with visual impairment due to diabetic macular edema: 24-month results of RETAIN study. ARVO conference, Orlando, Florida, 05/05/2014.
60. 60 Rajendram, R., Fraser-Bell, S., Kaines, A., et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 130:8 (2012), 972–979.
61. 61 Roh, M.I., Kim, H.S., Song, J.H., et al. Effect of intravitreal bevacizumab injection on aqueous humor cytokine levels in clinically significant macular edema. Ophthalmology 116:1 (2009), 80–86.
62. 62 Schmidt-Erfurth, U., Lang, G.E., Holz, F.G., et al., RESTORE extension study group. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 121 (2014), 1045–1053.
63. 63 Sharma, S., Oliver-Fernandez, A., Liu, W., et al. The impact of diabetic retinopathy on health-related quality of life. Curr Opin Ophthalmol 16 (2005), 155–159.
64. 64 Singerman LJ, Weichselberger A, Sallstig P. OSPREY trial: randomized, active-controlled, phase II study to evaluate safety and efficacy of RTH258, a humanized single-chain anti-VEGF antibody fragment, in patients with neovascular AMD. Paper presented at: Association of Research in Vision and Ophthalmology Annual Meeting; 2015 May 6; Denver, CO.
65. 65 Sivaprasad, S., Crosby-Nwaobi, R., Heng, L.Z., et al. Injection frequency and response to bevacizumab monotherapy for diabetic macular oedema (BOLT Report 5). Br J Ophthalmol 97:9 (2013), 1177–1180.
66. 66 Stumpp, M.T., Binz, H.K., Amstutz, P., DARPins: a new generation of protein therapeutics. Drug Discov Today 13:15-16 (2008), 695–701.
67. 67 Sultan, M.B., Zhou, D., Loftus, J., et al., Macugen 1013 Study Group. A phase 2/3, multicenter, randomized, double-masked, 2 year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthalmology 118:6 (2011), 1107–1118.
68. 68 Tolentino, M.J., McLeod, D.S., Taomoto, M., et al. Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133 (2002), 373–385.
69. 69 Tolentino, M.J., Miller, J.W., Gragoudas, E.S., et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103 (1996), 1820–1828.
70. 70 Varma, R., Bressler, N.M., Doan, Q.V., et al. Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 132:11 (2014), 1334–1340.
71. 71 Virgili, G., Parragano, M., Menchini, F., et al. Anti-vascular endothelial growth factor for diabetic macular edema. Cochrane Database Syst Rev(10), 2014, CD007419.
72. 72 Walker, J.M., Cove, D.H., Beevers, D.G., et al. Cigarette smoking, blood pressure and the control of blood glucose in the development of diabetic retinopathy. Diabetes Res 2:4 (1985), 183–186.
73. 73 Wessel, M.M., Nair, N., Aaker, G.D., et al. Peripheral retinal ischaemia, as evaluated by ultra-widefield fluorescein angiography, is associated with diabetic macular oedema. Br J Ophthalmol 96:5 (2012), 694–698.
74. 74 Wong, T.Y., Kelin, R., Islam, F.M., et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am J Ophthalmol 141:3 (2006), 446–455.
75. 75 Zhang, X., Bao, S., Lai, D., Rapkins, R.W., Gillies, M.C., Intravitreal triamcinolone acetonide inhibits breakdown of the blood-retinal barrier through differential regulation of VEGF-A and its receptors in early diabetic rat retinas. Diabetes 57:4 (2008), 1026–1033.
76. 76 Zhang, X., Zeng, H., Bao, S., Wang, N., Gillies, M., Diabetic macular edema: new concepts in patho-physiology and treatment. Cell Biosci, 4, 2014, 27.